Drug intelligence / Profile preview

SDN-1010

Development stage: Preclinical
Lead developer: Sidanis Pharma
Modality: Vaccines & Immunotherapeutics

Overview

SDN-1010 is a **preclinical glycoconjugate immunostimulator vaccine adjuvant** being developed by **Sidanis Pharma** for infectious disease prevention. It is described as a prototype of the company's glycoconjugate immunostimulator platform designed to **enhance adaptive immune responses** when co-administered with **low-immunogenic antigens**, including **inactivated viral vaccines, epitope vaccines, and recombinant vaccines**. Available nonclinical descriptions indicate that SDN-1010 functions as an immunostimulatory biologic adjuvant rather than as a standalone vaccine antigen, with reported preclinical activity including induction of high antibody titers and durable protective immunity in animal studies.

Other names: glycoconjugate immunostimulator vaccine adjuvantGCI vaccine adjuvant

Beyond the preview

Go deeper on SDN-1010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SDN-1010.

Explore the full profile